Phase II trial of MGCD 265 combination therapy in patients with non-small cell lung cancer.
Phase of Trial: Phase II
Latest Information Update: 06 Aug 2015
At a glance
- Drugs Glesatinib (Primary) ; Docetaxel; Erlotinib
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 06 Aug 2015 According to Mirati Therapeutics media release, company is planning to initiate this trial by the end of the year.
- 14 Jun 2010 New trial record